Pfizer Inc. $PFE Shares Sold by Public Employees Retirement System of Ohio

Key Points

• The Public Employees Retirement System of Ohio reduced its stake in Pfizer Inc. by **0.7%**, holding **2,317,180 shares** valued at approximately **$56.17 million** following the sale of **15,349 shares** in the second quarter.
• Institutional investors have shown significant interest in Pfizer, with **Pacer Advisors Inc.** increasing its stake by **856.8%**, and **Amundi** raising its holdings by **43.4%**, contributing to **68.36%** of the company's stock being owned by institutional entities.
• Pfizer reported a **Q2 earnings per share** of **$0.78**, exceeding estimates, and **revenue** of **$14.65 billion**, up **10.3%** year-over-year, with analysts projecting an EPS of **2.95** for the current year.

Public Employees Retirement System of Ohio decreased its position in Pfizer Inc. (NYSE:PFE - Free Report) by 0.7% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 2,317,180 shares of the biopharmaceutical company's stock after selling 15,349 shares during the period. Public Employees Retirement System of Ohio's holdings in Pfizer were worth $56,168,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in the stock. Pacer Advisors Inc. lifted its stake in Pfizer by 856.8% during the first quarter. Pacer Advisors Inc. now owns 20,053,828 shares of the biopharmaceutical company's stock valued at $508,164,000 after purchasing an additional 17,957,928 shares during the last quarter. Amundi increased its stake in shares of Pfizer by 43.4% during the 1st quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company's stock worth $1,265,277,000 after purchasing an additional 15,758,846 shares during the last quarter. Nuveen LLC acquired a new position in shares of Pfizer during the 1st quarter worth $389,861,000. Goldman Sachs Group Inc. increased its stake in shares of Pfizer by 51.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 26,456,457 shares of the biopharmaceutical company's stock worth $670,407,000 after purchasing an additional 9,041,990 shares during the last quarter. Finally, Assenagon Asset Management S.A. boosted its holdings in shares of Pfizer by 307.5% during the 1st quarter. Assenagon Asset Management S.A. now owns 10,046,340 shares of the biopharmaceutical company's stock worth $254,574,000 after buying an additional 7,581,030 shares during the period. 68.36% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the stock. Wall Street Zen raised shares of Pfizer from a "hold" rating to a "buy" rating in a report on Saturday. Citigroup raised their price objective on shares of Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a report on Wednesday, August 6th. Morgan Stanley raised their price objective on shares of Pfizer from $32.00 to $33.00 and gave the stock an "equal weight" rating in a report on Wednesday, August 6th. Bank of America raised their price objective on shares of Pfizer from $27.00 to $28.00 and gave the stock a "neutral" rating in a report on Wednesday, August 6th. Finally, Berenberg Bank reduced their price objective on shares of Pfizer from $28.00 to $25.00 and set a "hold" rating for the company in a report on Thursday, May 29th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Pfizer has an average rating of "Hold" and a consensus price target of $28.12.

Pfizer Stock Up 0.3%

Shares of NYSE PFE opened at $24.12 on Wednesday. The firm has a market capitalization of $137.14 billion, a PE ratio of 12.83, a price-to-earnings-growth ratio of 0.78 and a beta of 0.55. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $30.43. The firm's 50-day moving average is $24.60 and its 200-day moving average is $24.18.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.58 by $0.20. The company had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company's revenue for the quarter was up 10.3% on a year-over-year basis. During the same quarter last year, the firm earned $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.